Assenagon Asset Management S.A., a registered investment adviser, initiated a new position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during Q4 2025, according to its most recent 13F filing with the Securities and Exchange Commission.
The institutional investor purchased 832,853 shares of the Healthcare company, valued at approximately $377,582,236 as of the filing date.
Vertex Pharmaceuticals Incorporated's stock currently trades at $457.85 with a market capitalization of $114,461,471,944.